TD Cowen’s recent upgrade of Array Technologies (ARRY) has refocused attention on the solar tracker maker, as the firm cited improving execution, muted expectations, and a valuation gap versus peers.
Abstract: The effect of light illumination intensity on the stability of In-Zn-Sn-O (IZTO) thin-film transistors (TFTs) array fabricated by solution processed is investigated. Comparison with positive ...
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Ripple (CRYPTO: XRP) has processed $95 billion in payments in total, but XRP’s performance in 2025 ...
Europe salvages credibility with $105 billion loan for Ukraine but shelves plan to use Russian funds
European Union leaders reached a deal early Friday on a $105 billion loan to keep Ukraine’s economy and military from a budgetary blackhole through 2027. While it didn’t come about in the way some of ...
EUREKA, Calif., and ZHANGBEI COUNTY, China– Twenty miles off the misty northern coast of California, off of Humboldt Bay, there's a plan to build offshore wind turbines to power more than two million ...
There are two key things to know about the new Applied Biosystems™ SwiftArrayStudio™ Microarray Analyzer from Thermo Fisher Scientific, said Ravi Gupta, vice president and general manager of Thermo ...
Albuquerque-based Array Technologies reported Thursday a 20% jump in revenue from the previous quarter, beating analyst expectations. In an earnings call, company officials reported $362.2 million in ...
Nicole Fallon-Peek is a freelance journalist who has covered small business, careers and finance for 15 years. She is a small business owner and former managing editor of Business News Daily. Her work ...
Opus Genetics, Inc. announced positive topline results from its VEGA-3 Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% for treating presbyopia, achieving its primary and key ...
VEGA-3 trial showed significant efficacy of phentolamine ophthalmic solution 0.75% in improving near vision in presbyopia patients compared to placebo. The trial met its primary endpoint with 27.2% ...
To satisfy the seafood needs of billions of people, offering them access to a more biodiverse array of fish creates opportunities to mix-and-match species to obtain better nutrition from smaller ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results